Darapladib

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Darapladib
Darapladib structure.svg
Clinical data
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
  • Investigational
Identifiers
Synonyms SB-480848
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
ECHA InfoCard 100.130.738
Chemical and physical data
Formula C36H38F4N4O2S
Molar mass 666.77 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Darapladib is an inhibitor lipoprotein-associated phospholipase A2 (Lp-PLA2) that is in development as a drug for treatment of atherosclerosis.[1]

It was discovered by Human Genome Sciences in collaboration with GlaxoSmithKline (GSK).[2]

In November 2013, GSK announced that the drug had failed to meet Phase III endpoints in a trial of 16,000 patients with acute coronary syndrome (ACS).[3] An additional trial of 13,000 patients (SOLID-TIMI 52) finished in May 2014. The study failed to reduce the risk of coronary heart disease death, myocardial infarction, and urgent coronary revascularization compared with placebo in acute coronary syndrome patients treated with standard medical care.[4]

References[edit]